Assessment of therapeutic efficacy & safety of Sitopaladi Churna in the Management of Kasa (Stable chronic Bronchitis) - Kasa

Central Council For Research in Ayurvedic Sciences0 sites67 target enrollmentStarted: TBDLast updated: November 24, 2021

Trial Snapshot

No summary available.

•1.Patients of either sex aged between 18 to 65years.
•2.Patients suffering from Chronic Stable Bronchitis. (Chronic Bronchitis is defined as a cough that occurs every day with sputum production that lasts for at least three months, two years in a row).
•3.Patients having FEV1 > 80%.
•4.Patient willing and able to participate in the study for 16 weeks.

•1.Any other pulmonary diagnosis like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Asthma, Cystic fibrosis, Tuberculosis, Lung cancer etc.
•2.Known case of Diabetes Mellitus
•3.Patients with poorly controlled Hypertension ( >=160 / 100 mmHg).
•4.Patients on prolonged ( > 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
•5.Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders etc).
•6.Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•7.Symptomatic patients with clinical evidence of Heart failure.
•8.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL).
•9.Smokers/alcoholics and/or drug abusers.
•10.Patients who have completed participation in any other clinical trial during the past six (06) months.
•11.Any other condition which the Investigator thinks may jeopardize the study.

Sponsor